{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:19Z","timestamp":1793640739913,"version":"4.5.1"},"reference-count":80,"publisher":null,"issue":"9","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>Pulmonary hypertension (PH) can develop in different systemic autoimmune rheumatic diseases (SARD), such as systemic scleroderma (SSD), systemic lupus erythematosus, rheumatoid arthritis, and mixed connective tissue disease In most cases, patients with SARD develop WHO group I PH (pulmonary arterial hypertension associated with systemic connective tissue diseases, PAH-SCTD). General prevalence of this pathology reaches 15 cases per million adults. Most cases of PAH-SCTD are induced by SSD. Survival of PAH-SCTD patients is generally lower than survival of patients with other forms of LAH. Treatment of any SARD, including in LAH, implies a complex approach using glucocorticoids, disease-modifying anti-rheumatic drugs (cyclophosphamide, methotrexate, azathioprine, and others), and genetically engineered biologics. Specific targeted therapy is indicated for most patients with PAH-SCTD. The representative of a new class (soluble guanylate cyclase (sGC) stimulators), riociguat, has been approved for the treatment of PAH. This drug has a unique double mechanism of action: (i) sGC sensibilization to endogenous nitric oxide (NO) by stabilizing the NO-sGC bond; and (ii) direct, NO-independent sGC stimulation. For patients with PAH-SCTD, riociguat is the major alternative to phosphodiesterase-5 inhibitors both as monotherapy and combination therapy.<\/jats:p>","DOI":"10.18087\/cardio.2020.9.n1189","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T04:39:07Z","timestamp":1604291947000},"page":"92-101","source":"Crossref","is-referenced-by-count":0,"title":["The place of riociguat in the treatment of patients with pulmonary arterial hypertension associated with systemic connective tissue diseases"],"prefix":"10.68900","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-1006","authenticated-orcid":true,"given":"N. A.","family":"Shostak","sequence":"first","affiliation":[{"name":"Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9784","authenticated-orcid":true,"given":"A. A.","family":"Klimenko","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-8777","authenticated-orcid":true,"given":"N. A.","family":"Demidova","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"ref1","unstructured":"Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Barbarash O.L., Veselova T.N. et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Cardiology Journal. 2020;1(30):78\u2013122. DOI: 10.24411\/2076-4766-2020-10002"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal. 2015;46(4):903\u201375. DOI: 10.1183\/13993003.01032-2015","DOI":"10.1183\/13993003.01032-2015"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, Brundage BH, Detre KM, Fishman AP et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry. Annals of Internal Medicine. 1991;115(5):343\u20139. DOI: 10.7326\/0003-4819-115-5-343","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. DOI: 10.1183\/13993003.01913-2018","DOI":"10.1183\/13993003.01913-2018"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary Arterial Hypertension in France: Results from a National Registry. American Journal of Respiratory and Critical Care Medicine. 2006;173(9):1023\u201330. DOI: 10.1164\/rccm.200510-1668OC","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases. 2013;72(12):1940\u20136. DOI: 10.1136\/annrheumdis-2012-202489","DOI":"10.1136\/annrheumdis-2012-202489"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sanchez O, Sitbon O, Ja\u00efs X, Simonneau G, Humbert M. Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest. 2006;130(1):182\u20139. DOI: 10.1378\/chest.130.1.182","DOI":"10.1378\/chest.130.1.182"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al. Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL. Chest. 2010;138(6):1383\u201394. DOI: 10.1378\/chest.10-0260","DOI":"10.1378\/chest.10-0260"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Humbert M, Coghlan JG, Ghofrani H-A, Grimminger F, He J-G, Riemekasten G et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases. 2017;76(2):422\u20136. DOI: 10.1136\/annrheumdis-2015-209087","DOI":"10.1136\/annrheumdis-2015-209087"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. European Respiratory Review. 2012;21(123):8\u201318. DOI: 10.1183\/09059180.00008211","DOI":"10.1183\/09059180.00008211"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Fayed H, Coghlan JG. Pulmonary Hypertension Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine. 2019;40(02):173\u201383. DOI: 10.1055\/s-0039-1685214","DOI":"10.1055\/s-0039-1685214"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E et al. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Experimental Biology and Medicine. 2019;244(2):120\u201331. DOI: 10.1177\/1535370218824101","DOI":"10.1177\/1535370218824101"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Mukerjee D, George DSt, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases. 2003;62(11):1088\u201393. DOI: 10.1136\/ard.62.11.1088","DOI":"10.1136\/ard.62.11.1088"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis & Rheumatism. 2005;52(12):3792\u2013800. DOI: 10.1002\/art.21433","DOI":"10.1002\/art.21433"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gaine SP, Rubin LJ. Primary pulmonary hypertension. The Lancet. 1998;352(9129):719\u201325. DOI: 10.1016\/S0140-6736(98)02111-4","DOI":"10.1016\/S0140-6736(98)02111-4"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Chazova I.E., Arkhipova O.A., Martynyuk T.V. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Therapeutic Archive. 2019;91(1):25\u201331. DOI: 10.26442\/00403660.2019.01.000024","DOI":"10.26442\/00403660.2019.01.000024"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mayes MD. Scleroderma epidemiology. Rheumatic Disease Clinics of North America. 2003;29(2):239\u201354. DOI: 10.1016\/S0889-857X(03)00022-X","DOI":"10.1016\/S0889-857X(03)00022-X"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USAbased registry for pulmonary arterial hypertension: 1982 - 2006. European Respiratory Journal. 2007;30(6):1103\u201310. DOI: 10.1183\/09031936.00042107","DOI":"10.1183\/09031936.00042107"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis & Rheumatism. 2009;60(6):1831\u20139. DOI: 10.1002\/art.24525","DOI":"10.1002\/art.24525"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. European Respiratory Review. 2011;20(122):277\u201386. DOI: 10.1183\/09059180.00003811","DOI":"10.1183\/09059180.00003811"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bulletin De l\u2019Academie Nationale De Medecine. 2004;188(6):985\u201397; discussion 997. PMID: 15651427","DOI":"10.1016\/S0001-4079(19)33715-X"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Arnaud L, Agard C, Haroche J, Cacoub P, Piette J-C, Amoura Z. Hypertension art\u00e9rielle pulmonaire associ\u00e9e au lupus syst\u00e9mique. La Revue de M\u00e9decine Interne. 2011;32(11):689\u201397. DOI: 10.1016\/j.revmed.2011.01.002","DOI":"10.1016\/j.revmed.2011.01.002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ghofraniha L, Mirfeizi Z, Seyyedi Khabbaz F, Vakilian F, Eslami S. Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematous. Electronic Physician. 2017;9(8):5122\u20138. DOI: 10.19082\/5122","DOI":"10.19082\/5122"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Asif S, Rasheed A, Mahmud T-H, Asghar A. Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. Pakistan Journal of Medical Sciences. 2019;35(1):86\u20139. DOI: 10.12669\/pjms.35.1.405","DOI":"10.12669\/pjms.35.1.405"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest. 2012;142(2):448\u201356. DOI: 10.1378\/chest.11-1460","DOI":"10.1378\/chest.11-1460"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Manes A, Farahani KV, Pelino F, Palazzini M, Negro L et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005;14(9):713\u20137. DOI: 10.1191\/0961203305lu2206oa","DOI":"10.1191\/0961203305lu2206oa"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F et al. Connective Tissue Disease\u2013associated Pulmonary Arterial Hypertension in the Modern Treatment Era. American Journal of Respiratory and Critical Care Medicine. 2009;179(2):151\u20137. DOI: 10.1164\/rccm.200806-953OC","DOI":"10.1164\/rccm.200806-953OC"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM et al. Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest. 2014;146(6):1494\u2013504. DOI: 10.1378\/chest.13-3014","DOI":"10.1378\/chest.13-3014"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Min HK, Lee JH, Jung SM, Lee J, Kang KY, Kwok S-K et al. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. The Korean Journal of Internal Medicine. 2015;30(2):232\u201341. DOI: 10.3904\/kjim.2015.30.2.232","DOI":"10.3904\/kjim.2015.30.2.232"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. European Respiratory Journal. 2003;22(2):358\u201363. DOI: 10.1183\/09031936.03.00038903","DOI":"10.1183\/09031936.03.00038903"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nicolls MR, Voelkel NF. The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2017;195(10):1292\u20139. DOI: 10.1164\/rccm.201608-1630PP","DOI":"10.1164\/rccm.201608-1630PP"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Dhala A. Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Current Status and Future Direction. Clinical and Developmental Immunology. 2012;2012:854941. DOI: 10.1155\/2012\/854941","DOI":"10.1155\/2012\/854941"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sasaki N, Kamataki A, Sawai T. A Histopathological Study of Pulmonary Hypertension in Connective Tissue Disease. Allergology International. 2011;60(4):411\u20137. DOI: 10.2332\/allergolint.11-RAI-0337","DOI":"10.2332\/allergolint.11-RAI-0337"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Kato Y, Kasama T, Soejima M, Kubota T. Anti-enolase 1 antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells. Immunology Letters. 2020;218:22\u20139. DOI: 10.1016\/j.imlet.2019.12.005","DOI":"10.1016\/j.imlet.2019.12.005"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lee JH, Im Cho K. Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus. Journal of Cardiology. 2014;64(6):450\u20135. DOI: 10.1016\/j.jjcc.2014.02.030","DOI":"10.1016\/j.jjcc.2014.02.030"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Houman MH, Smiti-Khanfir M, Ghorbell IB, Miled M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus. 2004;13(3):204\u201311. DOI: 10.1191\/0961203303lu530xx","DOI":"10.1191\/0961203303lu530xx"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J et al. Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine. 2016;95(10):e2761. DOI: 10.1097\/MD.0000000000002761","DOI":"10.1097\/MD.0000000000002761"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":". Kahler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology. 2006;45(Suppl 3):iii11\u2013 3. DOI: 10.1093\/rheumatology\/kel291","DOI":"10.1093\/rheumatology\/kel291"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lai Y-C, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary Arterial Hypertension: The Clinical Syndrome. Circulation Research. 2014;115(1):115\u201330. DOI: 10.1161\/CIRCRESAHA.115.301146","DOI":"10.1161\/CIRCRESAHA.115.301146"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovascular Research. 2004;61(2):227\u201337. DOI: 10.1016\/j.cardiores.2003.11.026","DOI":"10.1016\/j.cardiores.2003.11.026"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Chester AH, Yacoub MH, Moncada S. Nitric oxide and pulmonary arterial hypertension. Global Cardiology Science and Practice. 2017;2017(2):14. DOI: 10.21542\/gcsp.2017.14","DOI":"10.21542\/gcsp.2017.14"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM et al. Role of prostacyclin in pulmonary hypertension. Global Cardiology Science and Practice. 2014;2014(4):382\u2013393. DOI: 10.5339\/gcsp.2014.53","DOI":"10.5339\/gcsp.2014.53"},{"key":"ref43","unstructured":"Chazova I.E., Martynyuk T.V. Pulmonary hypertension. \u2013 M.: Praktika;2015. - 928 p. [Russian: \u0427\u0430\u0437\u043e\u0432\u0430 \u0418.\u0415., \u041c\u0430\u0440\u0442\u044b\u043d\u044e\u043a \u0422.\u0412. \u041b\u0435\u0433\u043e\u0447\u043d\u0430\u044f \u0433\u0438\u043f\u0435\u0440\u0442\u0435\u043d\u0437\u0438\u044f. \u2013 \u041c.: \u041f\u0440\u0430\u043a\u0442\u0438\u043a\u0430, 2015. \u2013 928c]. ISBN 978-5-89816-138-5"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nature Reviews Drug Discovery. 2015;14(9):623\u201341. DOI: 10.1038\/nrd4623","DOI":"10.1038\/nrd4623"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Koshland D. The molecule of the year. Science. 1992;258(5090):1861\u20131861. DOI: 10.1126\/science.1470903","DOI":"10.1126\/science.1470903"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Chatterjee A, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascular Pharmacology. 2008;49(4\u2013 6):134\u201340. DOI: 10.1016\/j.vph.2008.06.008","DOI":"10.1016\/j.vph.2008.06.008"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Evgenov OV, Pacher P, Schmidt PM, Hask\u00f3 G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery. 2006;5(9):755\u201368. DOI: 10.1038\/nrd2038","DOI":"10.1038\/nrd2038"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nature Biotechnology. 2013;31(12):1064. DOI: 10.1038\/nbt1213-1064b","DOI":"10.1038\/nbt1213-1064b"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Shmal\u2019ts A.A., Gorbachevskiy S.V. Riociguat and sildenafil for pulmonary hypertension: similarity and difference. Russian Pulmonology. 2016;26(1):85\u201391. DOI: 10.18093\/0869-0189-2016-26-1-85-91","DOI":"10.18093\/0869-0189-2016-26-1-85-91"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review. 2017;26(145):170056. DOI: 10.1183\/16000617.0056-2017","DOI":"10.1183\/16000617.0056-2017"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Weatherald J, Montani D, Jevnikar M, Ja\u00efs X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review. 2019;28(153):190023. DOI: 10.1183\/16000617.0023-2019","DOI":"10.1183\/16000617.0023-2019"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. European Journal of Clinical Investigation. 2018;48(2):e12876. DOI: 10.1111\/eci.12876","DOI":"10.1111\/eci.12876"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al. Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Pulmonary Hypertension in Connective Tissue Diseases. Arthritis & Rheumatism. 2013;65(12):3194\u2013201. DOI: 10.1002\/art.38172","DOI":"10.1002\/art.38172"},{"key":"ref54","unstructured":"Nasonov E.L. Russian clinical guidelines. Rheumatology. -M.: GEOTAR-Media;2017. - 464 p. [Russian: \u041d\u0430\u0441\u043e\u043d\u043e\u0432 \u0415.\u041b. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438. \u0420\u0435\u0432\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. - \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2017. - 464\u0441]. ISBN 978-5-9704-4261-6"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Jais X, Launay D, Yaici A, Le Pavec J, Tch\u00e9rakian C, Sitbon O et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease\u2013associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis & Rheumatism. 2008;58(2):521\u201331. DOI: 10.1002\/art.23303","DOI":"10.1002\/art.23303"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Sobanski V, Launay D, Hachulla E, Humbert M. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports. 2016;18(2):10. DOI: 10.1007\/s11926-015-0560-x","DOI":"10.1007\/s11926-015-0560-x"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y et al. Intensive Immunosuppressive Therapy Improves Pulmonary Hemodynamics and Long-Term Prognosis in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circulation Journal. 2011;75(11):2668\u201374. DOI: 10.1253\/circj.CJ-11-0473","DOI":"10.1253\/circj.CJ-11-0473"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal. 2010;31(15):1898\u2013907. DOI: 10.1093\/eurheartj\/ehq170","DOI":"10.1093\/eurheartj\/ehq170"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Rouzic EML et al. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest. 2015;148(4):1043\u201354. DOI: 10.1378\/chest.15-0300","DOI":"10.1378\/chest.15-0300"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Stasch J-P, Pacher P, Evgenov OV. Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease. Circulation. 2011;123(20):2263\u201373. DOI: 10.1161\/CIRCULATIONAHA.110.981738","DOI":"10.1161\/CIRCULATIONAHA.110.981738"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Ghofrani H-A, Gali\u00e8 N, Grimminger F, Gr\u00fcnig E, Humbert M, Jing Z-C et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(4):330\u201340. DOI: 10.1056\/NEJMoa1209655","DOI":"10.1056\/NEJMoa1209655"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Rubin LJ, Gali\u00e8 N, Grimminger F, Gr\u00fcnig E, Humbert M, Jing Z-C et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal. 2015;45(5):1303\u201313. DOI: 10.1183\/09031936.00090614","DOI":"10.1183\/09031936.00090614"},{"key":"ref63","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Gali\u00e8 N et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. The Journal of Rheumatology. 2007;34(12):2417\u2013 22. PMID: 17985403"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial. Annals of Internal Medicine. 2000;132(6):425\u201334. DOI: 10.7326\/0003-4819-132-6-200003210-00002","DOI":"10.7326\/0003-4819-132-6-200003210-00002"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Denton CP, Pope JE, Peter H-H, Gabrielli A, Boonstra A, van den Hoogen FHJ et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Annals of the Rheumatic Diseases. 2007;67(9):1222\u20138. DOI: 10.1136\/ard.2007.079921","DOI":"10.1136\/ard.2007.079921"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE et al. Pulmonary Arterial Hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376\u201387. DOI: 10.1378\/chest.09-1140","DOI":"10.1378\/chest.09-1140"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. European Respiratory Journal. 2012;39(4):945\u201355. DOI: 10.1183\/09031936.00078411","DOI":"10.1183\/09031936.00078411"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. International Journal of Cardiology. 2013;168(2):871\u201380. DOI: 10.1016\/j.ijcard.2012.10.026","DOI":"10.1016\/j.ijcard.2012.10.026"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management. 2006;2(4):411\u2013 22. DOI: 10.2147\/vhrm.2006.2.4.411","DOI":"10.2147\/vhrm.2006.2.4.411"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery. 2006;5(8):689\u2013702. DOI: 10.1038\/nrd2030","DOI":"10.1038\/nrd2030"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Giaid A, Saleh D. Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine. 1995;333(4):214\u201321. DOI: 10.1056\/NEJM199507273330403","DOI":"10.1056\/NEJM199507273330403"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Kielstein JT, Bode-B\u00f6ger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al. Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(7):1414\u20138. DOI: 10.1161\/01.ATV.0000168414.06853.f0","DOI":"10.1161\/01.ATV.0000168414.06853.f0"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Migneault A, Sauvageau S, Villeneuve L, Thorin E, Fournier A, Leblanc N et al. Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide. American Journal of Respiratory and Critical Care Medicine. 2005;171(5):506\u201313. DOI: 10.1164\/rccm.200403-340OC","DOI":"10.1164\/rccm.200403-340OC"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacology & Therapeutics. 2009;122(3):216\u201338. DOI: 10.1016\/j.pharmthera.2009.02.009","DOI":"10.1016\/j.pharmthera.2009.02.009"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Archer SL, Djaballah K, Humbert M, Kenneth Weir E, Fartoukh M, Dall\u2019Ava-Santucci J et al. Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 1998;158(4):1061\u20137. DOI: 10.1164\/ajrccm.158.4.9802113","DOI":"10.1164\/ajrccm.158.4.9802113"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension. Chest. 2004;125(2):580\u20136. DOI: 10.1378\/chest.125.2.580","DOI":"10.1378\/chest.125.2.580"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(9):834\u201344. DOI: 10.1056\/NEJMoa1413687","DOI":"10.1056\/NEJMoa1413687"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(9):809\u201318. DOI: 10.1056\/NEJMoa1213917","DOI":"10.1056\/NEJMoa1213917"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Simonneau G, Corris PA, Ghofrani H-A, Klinger JR, Langleben D et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal. 2017;50(3):1602425. DOI: 10.1183\/13993003.02425-2016","DOI":"10.1183\/13993003.02425-2016"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Raina A, Benza RL, Farber HW. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. Pulmonary Circulation. 2017;7(3):741\u20136. DOI: 10.1177\/2045893217721694","DOI":"10.1177\/2045893217721694"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1189\/803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:43Z","timestamp":1793639863000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":80,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,15]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.9.n1189","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}